

Pursuing better quality in all processes

In recent years, the Sawai Group has achieved rapid growth with the success of upfront investment in production facilities and personnel in anticipation of expanding demand for generic drugs. In fiscal 2020, the Group recorded all-time high revenue despite the impact of a reduced number of medical consultations and other factors due to the spread of COVID-19.

Social issues



Rising medical expenses
Medical expenses
¥43.6 trillion

The Hyper-aging society
Percentage of Japanese population aged 65 or older
28.7%

Need for affordable and safe drugs

Increasing interest in QOL

Disparities in healthcare access



Achievements of value creation activities (FY2020)

Revenue **¥187.2 billion**

Core operating profit **¥34.0 billion**

ROE **5.8%**

Dividends per share **¥130**

Number of tablets sold **13.3 billion tablets**

Number of new products launched **44**

Number of inquiries handled **48,600**

Investment in new businesses (FY2021 to FY2023)

Maximum of **¥30.0 billion**

The Medium-Term Business Plan START 2024 has envisioned the orphan drug business, the digital medical devices business, and the health food business as three growth areas that the Sawai Group should cultivate and set a maximum of ¥30.0 billion as the amount to be invested over three years.

Value Provided

Always putting healthier lives first

Reducing the burden on patients from medical costs

Volume share of generic drugs **78.3%**

Access to healthcare / improving QoL

Extending healthy life expectancy (2001-2016)

Men + **2.74** years, women + **2.14** years

* Based on 2018 White Paper on the Aging Society, Cabinet Office

A sustainable health insurance system

Reduction in medical expenses

¥317.6 billion